通过ROCK1-Drp1信号通路,S1PR3对抗改善了性急性损伤中的内皮功能障碍
Zhipeng Xu1, Jueyue Yan1, Gan Luo2
1Department of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Molecular immunology
|February 15, 2026
概括
氨酸-1-酸盐受体3 (S1PR3) 通过损害内皮细胞和线粒体,驱动败血症中的损伤. 用脂质体药物阻断S1PR3可以保护功能,并减少败血症引起的急性损伤.
科学领域:
- 脏病理生理学脏病理生理学
- 内皮细胞生物学 内皮细胞生物学
- 线粒体医学是指线粒体医学.
背景情况:
- 氨酸-1-酸盐受体3 (S1PR3) 主要存在于内皮细胞中,并影响炎症过程.
- 在性急性损伤 (S-AKI) 的发展中S1PR3的具体作用尚不清楚.
- 这项研究研究了S-AKI期间内皮功能障碍中S1PR3的功能和机制.
研究的目的:
- 确定S-AKI中S1PR3在内皮功能障碍中的作用.
- 阐明S1PR3对S-AKI病原发生的潜在机制.
- 评估S-AKI中S1PR3抗剂的治疗潜力.
主要方法:
- 在小鼠中使用脂聚糖 (LPS) 诱导了性急性损伤 (S-AKI).
- 脏内皮功能和线粒体完整性使用流动细胞计,埃文斯蓝色染料试验和传输电子显微镜进行了评估.
- 在体外研究中使用了具有S1PR3抗剂 (TY-52156) 和脂质体配方的人类脉内皮细胞 (HUVEC).
主要成果:
- 在野生型小鼠中,LPS挑战增加了血清肌素,血液尿素和S1PR3表达,其中S1PR3局部化到内皮细胞.
- 与野生型小鼠相比,缺乏S1PR3 (S1pr3-/-) 的小鼠表现出改善的功能,减少白细胞透,增强ATP生产.
- S1PR3激活与线粒体功能障碍,细胞骨变化和增加内皮透性相关;在体外,TY-52156减轻了这些影响. 脂质体封装,特别是LP-Neg-TY-52156,提高了疗效,减少了内皮泄漏和功能障碍 in vivo.
结论:
- 内皮S1PR3是S-AKI中线粒体功能障碍和屏障破坏的关键因素.
- 用脂质体抗剂向S1PR3提供了一种有前途的治疗方法,以保持内皮完整性并减轻败血性损伤.
相关概念视频
01:29Acute Kidney Injury II: Pathophysiology
1.2K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.2K
01:22Acute Kidney Injury I: Introduction
828
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
828
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
354
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
354
01:29Acute Kidney Injury III: Clinical Manifestations
993
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
993
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:20Acute Kidney Injury V: Interprofessional Care
369
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
369